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Introduction
Central venous catheters (CVCs) are frequently used in patients
for a variety of indications such as cancer treatment, diagnostic
monitoring, parenteral nutrition, hemodialysis, cardiac pacing,
and administration of ﬂuids, blood products or medication [1].
The beneﬁt derived from a CVC may be offset by thrombosis
and associated complications, such as pulmonary embolism
(PE), CVC dysfunction, infection or loss of central venous
access. In the long term patients with thrombosis may suffer
from a post-thrombotic syndrome [1,2].
The CVC-related thrombosis is an issue of importance to
many clinicians, and insight into the different aspects is crucial
to guide decisions in treatment in often vulnerable patients in
daily practice. In medical literature, there is a lack of
uniformity and uncertainty about several entities of CVC-
related thrombosis. First, two types of CVC-related throm-
bosis must be clearly distinguished; i.e. clinically manifest and
subclinical thrombosis. Furthermore, the type of thrombosis
and the incidence is deﬁned by the diagnostic strategy in
patients with a CVC.
Anticipation of the risk of CVC-related thrombosis and the
identiﬁcation of certain high-risk patients who are prone to
develop thrombosis and secondary complications, is essential
to initiate early preventive measurements such as prophylactic
anticoagulation. The need for anticoagulant prophylaxis is
however still a subject of discussion [3,4]. Finally, for the
treatment of established CVC-related thrombosis, several
therapeutic options were evaluated in literature. General
recommendations of anticoagulant treatment, and whether
CVC removal is necessary or not, is warranted.
The primary aim of this review is to describe the diagnostic
methods and their performance, the incidence and risk factors,
complications, prevention and treatment of CVC-related
thrombosis from a practical clinical point of view. English
medical literature studies were retrieved by an extensive
Medline search (Pubmed) and bibliographies of the obtained
studies were crosschecked where necessary. For each subject,
only those studies with the strongest level of evidence, as
deﬁned and discussed in the subsequent paragraphs, were
selected and reviewed.
Diagnosis of CVC-related thrombosis
In view of diagnosis of CVC-related thrombosis, two types of
thrombosis can be distinguished; clinically manifest thrombosis
and subclinical thrombosis. Clinically manifest thrombosis is
deﬁned as thrombosis objectiﬁed by diagnostic imaging
(ultrasound, venography) upon overt symptoms and signs,
such as pain or tenderness, warmth, swelling or edema, bluish
discoloration or visible collateral circulation. Subclinical
thrombosis, deﬁned as thrombosis in the absence of signs
and symptoms, is demonstrated by screening diagnostic
imaging.Most thrombotic events associatedwith CVCs remain
subclinical, or complications such as PE are the ﬁrst presenting
symptom [5–7].
Radiologically, thrombosis can have a typical appearance
of enveloping sleeve surrounding the CVC (Fig. 1) or be
characterized by mural thrombosis adherent to the venous
vessel wall [8]. Mural thrombosis, present in approximately
30% of patients with CVCs, may cause subtotal stenosis
(Fig. 2) or occlusion of the venous lumen and lead to clinically
manifest thrombosis or associated complications [6]. Mural
thrombosis is often found near the entry site of the CVC into
the vessel or at the junction of large veins, although it may be
extended or located into adjacent venous segments or the right
atrium.
In the diagnostic work-up of CVC-related thrombosis,
diagnostic imaging upon a clinical suspicion of thrombosis is
mandatory. A diagnosis based solely on clinical symptoms and
signs of thrombosis is non-speciﬁc, as in deep vein thrombosis
(DVT) of the leg. In only about a third to a half of all patients
in whom thrombosis is clinically suspected, the diagnosis is
conﬁrmed [9–11].
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Contrast venography is widely recognized as the reference
standard in the diagnosis of thrombosis [12]. However,
ultrasound is most often used clinically, because it is non-
invasive, does not expose to ionizing radiation, can easily be
performed at the bedside and is well accepted by patients. In
modern ultrasonography, real time gray-scale images (B-mode)
are obtained and the criteria of non-compressibility (compres-
sion ultrasound) and direct visualization of thrombotic mater-
ial in the venous lumen can be used to establish the presence or
absence of thrombosis. Besides, real time changes in vessel
diameter due to respiration may detect occlusive thrombosis
more centrally located. In addition, Doppler techniques can
add the advantage of evaluation of blood-ﬂow. With pulsed
Doppler signals added to gray scale imaging (Duplex ultra-
sound) qualitative and quantitative information of blood ﬂow
can be obtained. Color Doppler Flow Imaging (CDFI)
displays blood ﬂow in color in addition to gray scale imaging.
A combination of all three modalities is called color duplex
ultrasound.
In symptomatic lower extremity DVT, compression ultra-
sonography has been validated in clinical practice [13],
but speciﬁcally for thrombosis associated with femorally
inserted CVCs, no studies are available in which ultrasound
was compared with venography. With regard to the upper-
extremity DVT, venography has high to moderate inter-
observer agreement rates (71%–83%) and can be used as
a reference test in clinical practice [14]. In several studies
the diagnostic accuracy of ultrasound in upper extremity
thrombosis compared with venography was evaluated.
For the purpose of this review, we selected those studies in
which ultrasound was compared with routine contrast venog-
raphy in the diagnosis of upper-extremity DVT in the entire
cohort of reported patients, and which results were independ-
ently interpreted by blinded observers. Overall, six studies were
retrieved (Table 1) in which patients with CVCs were included.
The reported sensitivity of ultrasound in the diagnosis of upper
extremity DVT among these studies ranged from 56% to
100%, whereas the speciﬁcity ranged from 77% to 100%
[10,11,15–18].
Reports speciﬁcally aimed at patients with CVCs are
limited to three studies only [16–18], Importantly, in patients
with CVC-related thrombosis, thrombosis tends to be located
more centrally than in patients with thrombosis not related
to CVCs [4]. As a consequence, the diagnostic technique of
ultrasound, and therefore the accuracy, in patients with
suspected thrombosis because of CVCs is different than those
without (history of) CVC. In one study continuous wave
Doppler without gray scale imaging only was used, a
technique hardly applied nowadays [18]. Applying modern
techniques, Duplex ultrasound was reported to have an
excellent speciﬁcity (100%), however the sensitivity was
substantially lower (56%) [17]. In another study, CDFI was
found to be more sensitive (sensitivity 94% speciﬁcity 96%)
[16].
Summary
In summary, reliable data on the accuracy of ultrasound in
CVC-related thrombosis are limited. In lower extremity
CVC-related thrombosis no studies are available. In upper
extremity CVC-related thrombosis speciﬁcally, only three
studies are available, of which CDFI had the best
performance (sensitivity 94%, speciﬁcity 96%). In view of
the advantages of ultrasound mentioned, and the high
speciﬁcity, patients with clinically suspected CVC-related
thrombosis, should undergo ultrasound initially. However,
the safety of withholding treatment in case of a negative
ultrasound in patients suspected for thrombosis is uncertain
[19]. As a consequence, in patients with normal ultrasound
additional venography could be performed. Alternative
strategies such as serially performed ultrasound, spiral CT
or MRI may be useful and of potential interest, but are not
validated yet.
Fig. 1. Ultrasonic appearance of a typical enveloping ﬁbrin sheath
demonstrated immediately after central venous catheter removal (Jugular
vein).
Fig. 2. Nearly occlusive mural thrombosis visualized by a ﬂow defect,
detected by Color Doppler Flow Imaging, just after central venous
catheter removal.
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Incidence and risk factors of CVC-related thrombosis
Incidence
In numerous studies the incidence of CVC-related thrombosis
has been evaluated. In most studies, clinically manifest
thrombosis was used as the primary endpoint. Among these
studies incidences ranging from 0% to 28% were reported
[20,21]. However, the decision to refer for diagnostic imaging
upon clinical signs and symptoms for thrombosis lacks
uniformity and may be subjective. A more reliable estimate is
given by studies in which routine diagnostic screening (ultra-
sound or venography) was used in consecutive patients with
CVCs to determine to assess a diagnosis of thrombosis. For the
purpose of this review these studies are selected and summar-
ized in Table 2, according to the indication for the CVC, i.e. the
underlying disease and the type of thrombosis (subclinical,
clinically manifest and overall) [5,6,8,22–44].
Overall, the reported incidences of CVC-related thrombosis
in these studies ranged widely from 2% to 67% (Table 2). The
wide range in observed incidence may be partly caused by
different diagnostic modalities (venography, ultrasound), the
used criteria, and patient- and CVC characteristics. On
average, a 30% cumulative incidence can be found in
hospitalized patients and the overall majority of thrombotic
events remained subclinical [6]. The percentage of clinically
manifest thrombosis in these studies ranged from 0% to 12%
(Table 2).
In some speciﬁc populations, such as patients with hemo-
philia, prospective (screening) studies are not available. In
cohort-studies with merely clinical manifest thrombosis as an
endpoint incidences ranged from 0% to 3% [45]. Whether in
patients with inherited bleeding disorders the risk of thrombo-
sis is reduced as compared with other patients, is not known
because of the lack of large studies in which all patients were
screened systematically for thrombosis.
Risk factors
The individual risk of CVC-related thrombosis in a patient is
the result of the interaction between patient characteristics, i.e.
inherited and acquired risk factors; and the CVC (Fig. 3).
There are numerous studies in which risk-factor analysis of
CVC-related thrombosis was performed. For inherited and
common acquired risk factors cohort studies were considered
to represent the highest level of evidence (level 1); case control
studies as level 2. For CVC characteristics, randomized trials
were considered to represent level 1 of evidence; cohort studies
as level 2.
Inherited coagulations disorders have been reported to
contribute substantially to CVC-related thrombosis in large
cohort studies (level 1). Factor V Leiden (FVL) was strongly
associated with clinically manifest thrombosis in patients who
underwent bonemarrow transplantation (n ¼ 277); i.e. 54%of
patients with FVL developed thrombosis, in comparison with
10% of patients without (Cox proportional hazard ratio 7.7)
[46]. In a large hospital population of 252 patients, the presence
of FVL and prothombin G20210A mutation increased the
overall risk of CVC-related thrombosis almost threefold [6].
Two other recent performed studies also suggested a contribu-
tion of these commonly inherited coagulations disorders
[47,48]. In contrast to these studies, a case–control study (level
2) reported no increased prevalence of FVL in patients with
CVC-related thrombosis as compared with the general western
population [49]. In children, similar risk estimates as in adults
have been reported. In cohort studies, the risk of thrombosis in
FVL carriers in pediatric patients was substantial in patients
with acute lymphoid leukemia, as well in mixed populations
[43,50,51].
With regard to common acquired risk factors of venous
thrombosis there are numerous studies of different level of
evidence. In cohort studies, the presence of cancer or active
cancer treatment in both, adults and children [6,44], prior
thrombo-embolism [32], acquired (temporary) hypercoaguable
state [43,52] and a high platelet count at CVC insertion [53]
were associated with thrombosis. Age was also associated with
CVC-related thrombosis; the risk was higher with increasing
age, and in very young children [24,44].
Many CVC characteristics have been associated with an
increased risk of CVC-related thrombosis. The type of CVC
may be an important factor in the development of
CVC-related thrombosis. CVCs composed of silicon or
Table 1 Diagnostic accuracy of Doppler-ultrasound in the diagnosis of upper extremity thrombosis with routine contrast venography as the reference
standard
Study [reference] Patients (n) CVC (%)* Technique Sensitivity (%) Speciﬁcity (%) Manifest/subclinical
Prandoni et al. [10] 58 14 CUS 96 94 Manifest
Prandoni et al. [10] 47 NI Duplex 81 77 Manifest
Prandoni et al. [10] 34 NI CDFI 100 93 Manifest
Baarslag et al. [11] 99 NI CDFI 82 82 Manifest
Baxter et al. [15] 19 74 CDFI 100 100 Manifest
Ko¨ksoy et al. [16] 44 100 CDFI 94 96 Mixed
Haire et al. [17] 43 100 Duplex 56 100 Mixed
Bonnet et al. [18] 40 100 Doppler 93 93 Mixed
CUS, compression ultrasound; CDFI, color Doppler ﬂow imaging; NI, not indicated.
*Percentage of patients with a central venous catheter (CVC).
For deﬁnition manifest/subclinical, see text.
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polyurethane are less often associated with local thrombosis
than CVCs made of polyethylene [35,54,36]. In addition, the
risk of thrombosis tends to increase with the number of CVC
lumina [5,55]. The role of the puncture-site of CVC insertion is
still much debated. In two randomized trails (level 1) in
intensive care unit patients insertion via the subclavian route
had a low risk of thrombosis as compared to a femoral route
(0% vs. 25%, respectively 6%) [56,57]. A similar observation
was found in a cohort (level 2) study in patients with
subclavian vein CVC as compared with jugular CVCs (11%
vs. 42%) [24]. In both studies patients were routinely screened
by ultrasound for CVC-related thrombosis. However, the
1. Inherited Risk-Factors
Factor V Leiden Cancer (treatment)
Age
Prior DVT
Hypercoaguable
state
Material (PVC)
Number of lumina
Location tip
Vascular trauma
Entry-site?
Thrombosis
3. Central Vein Catheter
2. Acquired Risk-Factors
Prothrombin G20210A
Fig. 3. Interaction of inherited, acquired risk-factors of thrombosis with catheter characteristics play an important role the development of central venous
catheter-related thrombosis.
Table 2 Incidence of CVC-related thrombosis amongst studies with routine diagnostic imaging performed in consecutive patients (Doppler-Ultrasound or
venography)
Study [reference] Population N Technique DVT % (manifest %) Location entry site CVC
Chastre et al. [22] ICU 33 V 67 (0) Jugular vein
Durbec et al. [23] ICU 70 V 36 (0) Femoral vein
Timsit et al. [24] ICU 208 D 33 (0) Subclavian & jugular vein
Wu et al. [25] ICU 81 D 56 (0) Jugular vein
Joynt et al. [26] ICU 124 D 10 (2) Femoral vein
Martin et al. [27] ICU 60 D 58 (2) Axillary vein
Stoney et al. [28] Cardiology 203 V 34 (3) Cephalic & jugular vein
Goto et al. [30] Cardiology 100 V 23 (0) Cephalic & subclavian vein
Lin et al. [29] Cardiology 109 D 6 (0) Cephalic & subclavian vein
Antonelli et al. [31] Cardiology 40 V 28 (5) Cephalic & subclavian vein
Van Rooden et al. [32] Cardiology 145 D 23 (2) Cephalic & subclavian vein
Valerio et al. [33] Oncology 18 V 33 (6) Subclavian vein
Brismar et al. [34] Oncology 53 V 36 Subclavian vein
Bozetti et al. [35] Oncology 52 V 28 (0) Subclavian vein
Haire et al. [5] Haematology 35 V 63 (9) Subclavian vein
Balesteri et al. [8] Oncology 57 V 56 (0) Subclavian vein
De Cicco et al. [37] Oncology 95 V 66 (6) Subclavian vein
Biﬃ et al. [38] Oncology 302 D 4 (2) Subclavian & cephalic vein
Luciani et al. [39] Oncology 145 D 12 (3) Subclavian vein
Harter et al. [40] Oncology 233 D 2 (0) Jugular vein
Lordick et al. [41] Haematology 43 D 30 (0) Jugular vein
Van Rooden et al. [42] Haematology 105 D 28 (12) Jugular & subclavian vein
Nowak-Gottl et al. [43] Pediatrics 163 D 11 (11) Subclavian vein
Beck et al. [44] Pediatrics 93 D 18 (8) Jugular & subclavian & femoral vein
Van Rooden et al. [6] Mixed 252 D 30 (7) Jugular & subclavian vein
V, venography; D, Doppler-ultrasound; DVT, deep venous thrombosis.
For deﬁnition of manifest, see text.
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methodology of comparing femoral with subclavian vein
thrombosis associated with CVCs can be debated as the
technique and accuracy of ultrasound in asymptomatic upper
and lower DVT differ. In a recent cohort study (level 2) in
children, the subclavian route had an increased risk of
thrombosis as compared with the jugular route as assessed
by a combination of routine venography and routine ultra-
sound [58]. In cohort studies, a left insertion side has been
reported to increase the risk of thrombosis [37,53,58] and with
a CVC tip position into the subclavian or innominate vein,
thrombosis was more often observed in comparison to a
superior caval vein or right atrial tip location [39]. Additional
factors in cohort studies that have been reported to increase
the risk of thrombosis are a percutaneous insertion procedure,
prior CVC at the same puncture site and a prolonged stay of
the CVC for over 2 weeks [58,59].
Summary
In summary, CVC-related thrombosis is a multicausal disease.
Prothrombotic factors (e.g. FVL) and the underlying disease
(cancer) may play an important role in the development of
CVC-related thrombosis. Some important CVC characteristics
increase the risk of thrombosis, such as the type and material
of the CVC, vascular trauma and the duration of stay of the
CVC.
Complications
Catheter related thrombosis may be associated with several
complications including PE, infection of the thrombus, CVC
dysfunction and subsequent loss of intravenous access and
post-thrombotic syndrome or recurrent thrombosis.
Pulmonary embolism
The reported incidence of PE as a complication of catheter-
related thrombosis varies. In only one study, all patients with
proven thrombosis systematically underwent screening for PE
(ventilation-perfusion scan) and a 15% cumulative incidence
was reported [60]. In other studies incidences of PE, using
merely clinical endpoints, varied greatly. Whereas incidences of
symptomatic PE up to 17% have been reported, others did not
observe any PE [61,62]. PE associated with CVC-related
thrombosis has been reported to be the cause of death [7,60].
Screening for PE if a diagnosis of CVC-related thrombosis is
established is usually not mandatory, as in most patients
anticoagulant treatment is initiated, eventually with a removal
of the CVC. A ﬁrm evidence regarding clinical outcome needs
however to be established prospectively.
Infection
The CVC-related thrombosis and CVC-related infection have
been reported to be associated [24,41,63,64]. The pathogenesis
of catheter-related infection seems to depend on the
development of thrombosis of the catheter. Several thrombo-
proteins were shown to increase the risk of subsequent infection
[65,66]. Results from a postmortem study in 72 patients with a
CVC at death revealed that in all patients with catheter-related
sepsis (n ¼ 7) mural thrombosis after a CVC was present, out
of a total number of 31 patients with thrombosis [63]. In a study
in 265 critically ill patients the risk of infection and sepsis was
2.6-fold increased in patients with catheter-related thrombosis
[24]. In 43 patients undergoing intensive chemotherapy, 13
patients had objectiﬁed subclinical thrombosis of whom 12
developed infection [41].
In addition, CVC-related infectionmay also increase the risk
of subsequent clinically manifest thrombosis. In one study
CVC-related infection increased the risk of thrombosis (24%)
markedly in comparison with those without infection (3%)
(relative risk 17.6) [64].
In the presence of CVC-related infection, it may be useful to
screen patients for thrombosis with ultrasound, even in the
absence of other clinical overt signs and symptoms. Whether
such a strategy is clinically beneﬁcial, improves clinical
outcome, and is cost-effective should be further investigated.
Early CVC removal and dysfunction
TheCVCdysfunction because of clot formationmay occur due
to obstruction within the CVC lumina, or occlusion due to an
enveloping sheath obstructing the CVC luminal tip. Clot
formation of the CVC has been identiﬁed as the principal cause
of catheter dysfunction in prospective follow-up studies. In a
study in 85 CVCs placed for hemodialysis, 16 (19%) clot
formation occurred leading to catheter malfunctioning requi-
ring removal of the catheter in all cases [67]. In another study in
92CVCs inserted for hemodialysis, 11CVCshad to be removed
because of catheter complications [68]. In six (55%) of these
cases, occlusion because of clot was the major reason for
removal of the catheter. In a study of 949 CVC placed for
ambulatory chemotherapy in cancer patients, 152 (18%) of the
catheters had to be removed because of complications [69]. In
this study infectionof theCVCwas the leading cause of removal
of the CVC, 47 (31%) out of 152 CVCs, but also 38 (25%), had
to be removed due to catheter-related thrombosis or dysfunc-
tion due to clot. In a large study based on the Strategic
HealthCare Programs National Database, catheter complica-
tions that occurred in 45 333CVCsused in anoutpatient setting
in a 17-month period between 1999 and 2000 were evaluated
[70]. In 1871 catheters, dysfunction occurred and in 511 (27%)
cases dysfunction occurred as a consequence of clot formation.
In this study different types of central catheters were shown to
carry a different complication rate but thrombosis was themost
commonly reported cause of catheter dysfunction for periph-
erally and centrally inserted CVC with implantable ports.
Post-thrombotic syndrome and recurrent DVT
The incidence of the post-thrombotic syndrome, characterized
by venous hypertension, swelling of the extremity and pain [10],
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has been studied in patients without a CVC who experienced
an episode ofDVT. In such patients, an incidence of up to 80%
of the post-thrombotic syndrome has been reported [71].
However, data on post-thrombotic syndrome occurring as a
sequela of CVC-related thrombosis are scarce and show
contradictory results. Hingorani et al. reported a cumulative
incidence of 4%, whereas Hicken found a much higher
cumulative incidence of 50% [62,72]. In a prospective study
of a large group of 405 children with various diseases who all
developed thrombosis of the upper or lower extremity, 244
(60%) had a CVC [73]. Of these 405 children, 40% had
thrombosis of the lower and 60% had thrombosis of the upper
extremity. Post-thrombotic syndrome was found to occur in 50
(12%) of the 405 children. Of the 50 children who developed a
post-thrombotic syndrome, 23 had aCVC. In this study a CVC
was not an indicator for post-thrombotic syndrome (OR 0.59;
95% CI 0.28–0.94).
There are no reliable data concerning recurrent DVT after
an episode of proven CVC-related thrombosis.
Summary
In summary PE is an understudied and probably underdiag-
nosed complication of catheter-related thrombosis and to-
gether with infection of the thrombus a serious life-threatening
complication. In clinical practice, an established diagnosis of
infection may render it worthwhile to screen for thrombosis
with ultrasound. Besides, luminal clot is the most commonly
reported cause of catheter malfunctioning and removal of the
catheter. The post-thrombotic syndrome causes severe mor-
bidity, however, whether a CVC is an important risk factor is
unclear.
Prevention
In several studies among different patient populations the
effectiveness of anticoagulant prophylaxis was evaluated.
Basically, three groups of patients were distinguished:
(i) patients with hematological or solid tumor malignancies;
(ii) non-cancer patients (usually patients with parenteral
nutrition); and (iii) critically ill patients. For the purpose of
this review three types of studies, according to level of evidence,
are discussed subsequently (Table 3): (i) Randomized-con-
trolled studies with routine diagnostic imaging (venography or
ultrasound) to deﬁne CVC-related thrombosis as an endpoint.
Interpretation of data was blindly assessed. (Level 1); (ii) Rand-
omized-controlled studies (double-blind) with clinically mani-
fest thrombosis (or associated complications) as the primary
endpoint (Level 2); and (iii) Observational studies which
evaluated routine implementation of anticoagulant prophylaxis
in a cohort of consecutive patients compared with historical
controls without (Level 3).
Adult and pediatric populations are discussed separately.
RCT with routine diagnostic imaging
Three randomized-controlled trials (RCTs) in which routine
diagnostic imaging was used were performed in adult cancer
Table 3 Studies in which the beneﬁt from anticoagulant prophylaxis for CVC-related thrombosis was evaluated. Studies were classiﬁed into three
categories: (i) randomized-controlled trials with routinemandatory diagnostic imaging; (ii) randomized-controlled trials with clinicallymanifest thrombosis
or associated complications; and (iii) observational studies
Study [reference] Population n Intervention
Thrombosis
(%)
Thrombosis
(%) (controls) Endpoint
Randomized-controlled trials – mandatory diagnostic imaging
Bern et al. [74] Oncology 82 Warfarin 1 mg 9.5 42 Mandatory venogram
Monreal et al. [75] Oncology 29 Dalteparin 2500 IU 6 62 Mandatory venogram
Abdelkeﬁ et al. [76] Hematology 128 UFH (100 IU kg)1) 1.5 12.6 Mandatory ultrasound
Brismar et al. [34] Nutrition 49 UFH (5000 IU q 6 h) 21.7 53.8 Mandatory venogram
Ruggiero and
Aisenstein [80]
Nutrition 34 UHF (1000 IU L)1) 53 65 Mandatory venogram
Fabri et al. [81] Nutrition 46 UFH (3000 IU L)1) 8.3 31.8 Mandatory venogram
Fabri et al. [82] Nutrition 40 UFH (3000 IU L)1) 0 0 Mandatory venogram
Macoviak et al. [79] Nutrition 37 UHF (1 U ml)1) 17.6 15.6 Mandatory venogram
Pierce et al. [78] Pediart. Crit. Ill 209 UFH bonded CVC 8 0 Mandatory ultrasound
Massicotte et al. [77] Pediatr. Oncology 158 Reviparin 30–50 IU kg)1 14.1 12.5 Mandatory venogram
Randomized-controlled trials – Clinical endpoints
Heaton et al. [84] Hemato-oncology 88 Warfarin 1 mg 17.7 11.6 Including PE &
malfunction
Anderson et al. [85] Oncology 255 Warfarin 1 mg 4.6 4 No PE or malfunction
Reichardt et al. [83] Oncology 425 Dalteparin 5000 IU 3.4 3.7 No PE, malfunction
Cohort studies (consecutive patients vs. controls)
Boraks et al. [86] Hemato-Oncology 223 Warfarin 1 mg 5 13 CMT
Lagro et al. [87] Hemato-Oncology 323 Nadroparin 2850 IU 7 6 CMT
Lagro et al. [87] Hemato-Oncology 323 Nadroparin 5600 IU 8 6 CMT
UHF, unfractionated heparin; RR, risk reduction; CMT, clinically manifest thrombosis; PE, pulmonary embolism.
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patients, and two in pediatric populations [74–78] and ﬁveRCT
in patients receiving parenteral nutrition [34,79–82].
Cancer patients In cancer patients with subclavian CVCs,
Bern et al. [74] studied the beneﬁt of a randomly allocated ﬁxed
low dose warfarin (1 mg once daily orally) compared with
controls without. Among patients on warfarin a substantially
lower frequency of CVC-related thrombosis, as demonstrated
by venogram, was observed (9.5% vs. 42% in controls).
Monreal et al. [75] observed a similar beneﬁt from a
low molecular weight heparin (Dalteparin 2500 IU
subcutaneously) in cancer patients with subclavian inserted
Port-a-Caths. In patients on Dalteparin a 6% rate in
thrombosis was observed by routine venogram, as compared
with 62% in patient without. In a recent study in 128 hemato-
oncology patients a beneﬁt from continuously administered
unfractionated heparin (UFH) (100 IU kg)1 day)1) was
observed [76]. In the heparin group a 1.5% of patients were
diagnosed with thrombosis by routine ultrasound, in the
control group 12.6%. There were three events of severe
bleeding in the heparin group, as compared with two in the
control group (P ¼ NS). Combining the results of Monreal
et al. and Abdelkeﬁ et al. revealed a clear beneﬁt from heparin
as compared with placebo in adult cancer patients (RR 0.11;
95% CI 0.03–0.45).
In a study of 158 children with hematological malignancies
no substantial beneﬁt was obtained with a LMWH as
prophylaxis [77]. A total of 14% (11 of 78) of patients on
LMWHand 13% (10 of 80) in control patients got thrombosis.
In critically ill children, the effect of a heparin bonded catheter
has been evaluated to reduce the risk of thrombosis [78]. A
signiﬁcant reduction in thrombosis from 8 of 103 (8%) to 0 of
97 was observed [78].
Non-cancer patients/parenteral nutrition In patients who
received parenteral nutrition, only the beneﬁt of UFH in
various dosages added to the infusate has been assessed
(Table 3). The statistically power of these studies was however
limited, because of the small number of patients of each study.
Combining the results of these studies, a trend in risk reduction
of thrombosis by adding UFH to the infusate was calculated
(RR 0.6; 95% CI 0.34–1.06).
RCT with clinical endpoints
Cancer patients In RCTs with clinically manifest thrombosis
as a primary endpoint no clear beneﬁt from anticoagulant
prophylaxis was noticed in all three available studies [83–85]
(Table 3). Remarkably, the absolute risk of clinically manifest
thrombosis in the control group without anticoagulant
prophylaxis was low in all these studies (4%), which might
explain the lack of statistical power of these studies. The reason
for the discrepancy with observational studies with incidences
of up to 13% (Table 3) is unclear, but may be caused
by selection of patients or referral criteria for diagnostic
imaging.
There have been no studies in non-cancer patients or
critically ill patients or pediatric patients in this category of
studies.
Observational studies
Cancer patients In cancer patients two cohort studies were
performed which evaluated the effect of LMWH (two
regimens) or a ﬁxed low dose warfarin on CVC-related
thrombosis (Table 3) [86,87]. In a study among hematology
patients a ﬁxed low dose warfarin (1 mg orally) revealed a 5%
clinically manifest thrombosis, as compared with 13% in
historical controls without [86]. In another study with
retrospective controls, a 7- (2850 IU) and 10-day (5700 IU)
course of a LMWH in hematology patients was analyzed.
Overall, there was no difference in the cumulative incidence of
clinicallymanifest thrombosis between the groups who received
nadroparin (7% and 8% respectively) and those without (6%)
[87]. However, in this study most thrombotic events occurred
after stopping prophylaxis while the CVC remained in place. It
is unknown whether a prolongened course would have been
effective.
Combining the results of RCT and cohorts-studies, neither
an effect of warfarin or heparin was calculated, with regard to
the risk of clinically CVC-related thrombosis (warfarin: RR
0.72, 95% CI 0.27–1.9; heparin 0.92, 95% CI 0.57–1.49).
In order to reduce CVC the risk of intraluminal clot
formation or dysfunction ﬂushing or locking CVCs with UFH
is performed routinely inmany clinics.Whether such strategy is
more beneﬁcial as compared with saline is unsure. Currently
there are no reliable data addressing this theme with clearly
deﬁned endpoints including routine assessment by contrast
linogram, ultrasound/venography, response-rate to subsequent
thrombolysis and safety.
Summary
In summary, the risk of thrombosis may be reduced by
applying routine anticoagulant prophylaxis in patients with
CVCs in cancer patients. However, a clear beneﬁt was only
demonstrated in cancer patients who underwent mandatory
diagnostic imaging, including risk reduction of subclinical
events. It is therefore debatable whether routine implementa-
tion of prophylaxis for CVCs is warranted. Besides, the safety
of anticoagulant prophylaxis, a matter of serious concern
especially with regard to patients with cancer, has not been
studied well. In a recent survey, it was reported that a major
reason for clinicians not to comply with consensus guidelines
was the risk of bleeding due to thrombocytopenia, which
presumably outweighed the risk of thrombosis, particularly in
patients with cancer [88–90]. In this view, individualized
strategies upon allocation of risk assessment in certain vulner-
able patients with CVCs and a high risk of thrombosis – such as
those with (chemotherapy induced) thrombocyptopenia –
might be potentially useful to guide decisions on anticoagulant
prophylaxis.
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In non-cancer patients or critically ill patients no clear beneﬁt
from anticoagulant prophylaxis was observed. Available data
consisted of small studies. With the improvement of CVC
material no deﬁnite recommendations in these groups of
patients can be made, until a large interventions study becomes
available.
In critically ill children one study showed a risk reduction of
CVC thrombosis using heparin bonded CVCs. These CVCs
might be a safe alternative to systemic prophylactic anticoag-
ulation, and this needs to be evaluated in other populations in
need for short term catheterization.
Treatment
For the treatment of CVC-related thrombosis, various options
are available. Anticoagulant treatment, removal or replace-
ment of the CVC, or thrombolytic therapy may be used after a
diagnosis of thrombosis is established. In this review random-
ized-controlled intervention-trials evaluating the recurrence
rate of thrombosis and complications, and safety of therapy are
considered most convincingly (level 1), cohort studies as level 2,
case series as level 3.
Currently, no randomized trails have appeared in the
literature. In one cohort study, 112 cancer patients with
catheter-related thrombosis, a diversity of therapeutic interven-
tions (several anticoagulation strategies with or without CVC
removal)were shownnot to result inmajordifferences in clinical
outcome [61]. Treatment consisted of anticoagulation (n ¼ 39),
anticoagulation with CVC removal or replacement (n ¼ 22),
CVCremovalor replacement (n ¼ 32),other therapy (n ¼ 7)or
no therapy (n ¼ 8). In no patients recurrent DVT or secondary
complications or death of unknown cause occurred within
2 weeks of diagnosis, while in four patients with CVC replace-
ment only symptoms of edemawere persistent. In a prospective
case-series of 46 outpatients with upper extremity DVT, in
whom 16 (35%) had a central-vein catheter, showed that
LMWH(Dalteparin200aXaIU kg)1) foraminimumof5 days
together with oral anticoagulants was shown to be safe and
effective [91] Evaluation after 12 weeks showed one recurrent
DVT (2%), no secondary complications ofDVTand onemajor
bleeding event (2%). However, seven patients died, all presum-
ably to underlying disease. Another study evaluated 36 patients
with proven DVT of the upper extremity, mostly related to
CVCs, up to 1 year after the diagnosis. With LMWH followed
by oral anticoagulants (6 months), no recurrent DVT or
secondary complications were noted. Nine patients died,
presumably due to underlying disease (25%) [92].
A number of non-randomized studies of thrombolytic
therapy in catheter related thrombosis have been carried out
[93–96]. In a retrospective analysis of 95 patients with an upper-
extremity thrombosis of whom 62 patients were treated with
anticoagulants and 33 with systemic thrombolysis, it was
shown that in 21%of the patients, bleeding complications were
observed after thrombolysis compared with no complications
in the group of anticoagulants only [97]. Besides, in the long
term no clinical differences with regard to recurrent DVT and
post-thrombotic syndrome were observed between thrombo-
lysis and anticoagulation.
For the treatment of ﬁbrin sheaths or luminal occlusion
which can lead to CVC dysfunction, the ﬁrst choice of therapy
is local thrombolytic therapy with low dose tissue plasminogen
activator [98,99] or urokinase [100,101]. After 2-h treatment
with 2 mg per 2 mL recombinant tissue plasminogen activator
(Alteplase), function was restored to 74% in the alteplase arm
and 17% in the placebo arm (P < 0.0001 compared with
placebo) [98]. After another dose (2 mg per 2 mL), function
was restored in 90% of patients. There were no serious study-
drug-related adverse events, no intracranial hemorrhage, no
major hemorrhage, and no embolic events [98]. Similar results
were conﬁrmed in a large randomized trial in over 1000 patients
[99].
Summary
In summary, the treatment of catheter-related thrombosis is
controversial. There are no randomized designed studies on the
best treatment of catheter-related thrombosis, but in most
cohort studies anticoagulant therapy is given. The necessity to
remove the catheter depends on the underlying diagnosis and
need for vascular access. There is a deﬁnite need for well
designed studies evaluating the optimal treatment in CVC-
related thrombosis. Because of the high rate of complications
during systemic thrombolysis, this therapy should be reserved
to life-threatening or extremity-threatening venous thrombosis.
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